No profile data available.
Nurix Therapeutics, Inc. (NRIX) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in Brisbane, United States, with about 317 full-time employees.
It reported revenue of $83.98 million for fiscal year 2025, up 54.0% from fiscal year 2024, and net income of -$264.46 million. In Q2 2026 (the quarter ended May 31, 2026) revenue was $9.04 million, down 79.5% from a year before. Its market capitalization was $2.32 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended November 30, 2025; market data as of October 9, 2026.
, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases.
Nurix Therapeutics reported $83.98 million in revenue for fiscal year 2025, up 54.0% from $54.55 million in fiscal year 2024. In Q2 2026 revenue was $9.04 million.
$2.32 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Beam Therapeutics Inc. (BEAM), Terns Pharmaceuticals, Inc. (TERN), Adma Biologics, Inc. (ADMA), Prestige Consumer Healthcare Inc. (PBH).